LABP - Landos Biopharma gets dosing underway in early-stage LABP-104 lupus study

Landos Biopharma (NASDAQ:LABP) has dosed the first subject in a Phase 1 study of LABP-104, a potentially first-in-class oral, small-molecule LANCL2 agonist, for the treatment of systemic lupus erythematosus. Systemic lupus erythematosus (SLE) is the most common type of the autoimmune disease lupus. The trial is a randomized, placebo-controlled, double-blind, ascending dose, multi-cohort study designed to evaluate the safety, tolerability and pharmacokinetics of LABP-104 in healthy volunteers. The primary endpoint will measure the safety and tolerability of LABP-104, while secondary endpoint will measure the pharmacokinetics. The company expects to report topline results of the Phase 1 trial in the first half of 2022.

For further details see:

Landos Biopharma gets dosing underway in early-stage LABP-104 lupus study